Standout Papers

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase... 2023 2026 2024175
  1. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023)
    William J. Sandborn, Séverine Vermeire et al. The Lancet

Immediate Impact

1 from Science/Nature 62 standout
Sub-graph 1 of 23

Citing Papers

Understanding the therapeutic toolkit for inflammatory bowel disease
2025 Standout
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
2024 Standout
3 intermediate papers

Works of Sheldon Sloan being referenced

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
2023 Standout
105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL
2021

Author Peers

Author Last Decade Papers Cites
Sheldon Sloan 1005 1064 177 195 45 1.3k
George Karamanolis 1005 889 115 106 71 1.7k
Jin-Yong Kang 768 569 165 110 43 1.2k
William Lipshutz 816 674 41 266 23 1.4k
Vincenzo Savarino 954 931 57 137 24 1.2k
Danny De Looze 781 810 41 151 51 1.4k
Jan A. J. M. Taminiau 759 679 315 36 42 1.5k
Maurice L. Kelley 733 315 468 123 55 1.4k
J. S. A. Collins 864 643 48 49 44 1.1k
Véronique Vitton 1327 570 130 82 94 1.6k
Luigi Dall’Oglio 1260 493 75 245 68 1.6k

All Works

Loading papers...

Rankless by CCL
2026